Sesame simplifies access to Zepbound for eligible patients

Sesame, known for providing affordable healthcare in the U.S., has partnered with Gifthealth to improve access to Lilly's obesity medication, Zepbound. This integration simplifies the process for eligible patients without insurance coverage to order and pay for Zepbound. Eligible patients will pay $349 for a 2.5mg single vial and $499 for 5mg, 7.5mg, or 10mg doses. This initiative is part of Sesame's "Success by Sesame" program, which aims to deliver an affordable weight loss solution. David Goldhill, co-founder and CEO of Sesame, emphasized the importance of making medications like Zepbound more accessible. He believes that this integration helps patients receive the necessary treatment easily and at a lower price. Gifthealth's EVP, Robert Hoppe, shared that they are committed to simplifying access to critical medications. This partnership aims to eliminate barriers for patients who pay out-of-pocket. The "Success by Sesame" program costs $89 monthly, excluding medication costs. It includes video visits with licensed providers, lab evaluations, and personalized care. Patients can choose their own provider to discuss treatment options. Nearly 246 million American adults are overweight or obese, and many are uninsured. Zepbound is recognized as an effective weight loss medication. Clinical trials have shown significant weight loss among participants using it. Sesame's unique marketplace fosters competition among healthcare providers, resulting in lower prices and increased convenience. This system allows patients to receive personalized care while avoiding the complexities of insurance.